{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T01:24:41Z","timestamp":1793928281579,"version":"4.8.0"},"reference-count":35,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100006093","name":"Patient-Centered Outcomes Research Institute","doi-asserted-by":"publisher","award":["DB-2020C2-20306"],"award-info":[{"award-number":["DB-2020C2-20306"]}],"id":[{"id":"10.13039\/100006093","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacejournalendocrinepractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrine Practice"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.eprac.2026.04.004","type":"journal-article","created":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T16:41:42Z","timestamp":1775666502000},"page":"1353-1361","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cardiovascular Effects of Alogliptin, Linagliptin, Saxagliptin, and Sitagliptin: A Target Trial Emulation of a Comparative Effectiveness Study"],"prefix":"10.1016","volume":"32","author":[{"given":"Urja N.","family":"Kalathiya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly","family":"Yuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3671-3622","authenticated-orcid":false,"given":"Jeph","family":"Herrin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kavya Sindhu","family":"Swarna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yihong","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric C.","family":"Polley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4734-7402","authenticated-orcid":false,"given":"Joshua J.","family":"Neumiller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9295-3225","authenticated-orcid":false,"given":"Rodolfo J.","family":"Galindo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3252-5026","authenticated-orcid":false,"given":"Guillermo E.","family":"Umpierrez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9218-3320","authenticated-orcid":false,"given":"Joseph S.","family":"Ross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan P.","family":"Brito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0595-2898","authenticated-orcid":false,"given":"Victor M.","family":"Montori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bijan J.","family":"Borah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bradley A.","family":"Maron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mindy M.","family":"Mickelson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2289-3183","authenticated-orcid":false,"given":"Rozalina G.","family":"McCoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eprac.2026.04.004_bib1","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.2147\/DMSO.S445114","article-title":"Efficacy and safety of the utilization of dipeptidyl peptidase IV inhibitors in diabetic patients with chronic kidney disease: a meta-analysis of randomized clinical trials","volume":"17","author":"Mahzari","year":"2024","journal-title":"Diabetes Metab Syndr Obes"},{"issue":"6","key":"10.1016\/j.eprac.2026.04.004_bib2","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1111\/j.1463-1326.2011.01540.x","article-title":"Saxagliptin and sitagliptin in adult patients with type 2 diabetes: a systematic review and meta-analysis","volume":"14","author":"Gerrald","year":"2012","journal-title":"Diabetes Obes Metab"},{"issue":"suppl_2","key":"10.1016\/j.eprac.2026.04.004_bib3","doi-asserted-by":"crossref","first-page":"S223","DOI":"10.2337\/dc09-S315","article-title":"Incretin-based therapies: viewpoints on the way to consensus","volume":"32","author":"Nauck","year":"2009","journal-title":"Diabetes Care"},{"issue":"10","key":"10.1016\/j.eprac.2026.04.004_bib4","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.2337\/dc21-0529","article-title":"Prescribing trends of antidiabetes medications in patients with type 2 diabetes and diabetic kidney disease, a cohort study","volume":"44","author":"Harris","year":"2021","journal-title":"Diabetes Care"},{"issue":"10","key":"10.1016\/j.eprac.2026.04.004_bib5","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1016\/j.amjcard.2020.01.053","article-title":"Contemporary trends in prescription of dipeptidyl Peptidase-4 inhibitors in the context of US food and drug administration warnings of heart failure risk","volume":"125","author":"Vaduganathan","year":"2020","journal-title":"Am J Cardiol"},{"issue":"1","key":"10.1016\/j.eprac.2026.04.004_bib6","doi-asserted-by":"crossref","first-page":"27","DOI":"10.4103\/mgmj.mgmj_74_24","article-title":"Trends in prescribing dipeptidyl peptidase-IV-based therapy for type 2 diabetes mellitus and determining factors associated with its utilization","volume":"12","author":"Singh","year":"2025","journal-title":"MGM J Med Sci"},{"issue":"14","key":"10.1016\/j.eprac.2026.04.004_bib7","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1056\/NEJMoa1307684","article-title":"Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus","volume":"369","author":"Scirica","year":"2013","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.eprac.2026.04.004_bib8","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1001\/jama.2019.13772","article-title":"Effect of Linagliptin vs glimepiride on major adverse cardiovascular outcomes in patients with type 2 diabetes: the CAROLINA randomized clinical trial","volume":"322","author":"Rosenstock","year":"2019","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.eprac.2026.04.004_bib9","doi-asserted-by":"crossref","first-page":"490","DOI":"10.2337\/cd22-0100","article-title":"Health care provider prescribing habits and barriers to use of new type 2 Diabetes Medications: a Single-System Survey Study","volume":"41","author":"Yaseen","year":"2023","journal-title":"Clin Diabetes"},{"issue":"1","key":"10.1016\/j.eprac.2026.04.004_bib10","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1001\/jama.2018.18269","article-title":"Effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk: the CARMELINA randomized clinical trial","volume":"321","author":"Rosenstock","year":"2019","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.eprac.2026.04.004_bib11","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1056\/NEJMoa1501352","article-title":"Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes","volume":"373","author":"Green","year":"2015","journal-title":"N Engl J Med"},{"issue":"9982","key":"10.1016\/j.eprac.2026.04.004_bib12","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1016\/S0140-6736(14)62225-X","article-title":"Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial","volume":"385","author":"Zannad","year":"2015","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.eprac.2026.04.004_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacadv.2024.100852","article-title":"Derivation of an annualized claims-based major adverse cardiovascular event estimator in type 2 diabetes","volume":"3","author":"McCoy","year":"2024","journal-title":"JACC Adv"},{"issue":"8","key":"10.1016\/j.eprac.2026.04.004_bib14","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1093\/aje\/kwv254","article-title":"Using big data to emulate a target trial when a randomized trial is not available","volume":"183","author":"Hern\u00e1n","year":"2016","journal-title":"Am J Epidemiol"},{"issue":"8","key":"10.1016\/j.eprac.2026.04.004_bib15","doi-asserted-by":"crossref","first-page":"W163","DOI":"10.7326\/0003-4819-147-8-200710160-00010-w1","article-title":"Strengthening the reporting of observational studies in epidemiology (STROBE): explanation and elaboration","volume":"147","author":"Vandenbroucke","year":"2007","journal-title":"Ann Intern Med"},{"issue":"7","key":"10.1016\/j.eprac.2026.04.004_bib16","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1377\/hlthaff.2014.0038","article-title":"Optum Labs: building a novel node in the learning health care system","volume":"33","author":"Wallace","year":"2014","journal-title":"Health Aff"},{"key":"10.1016\/j.eprac.2026.04.004_bib17","series-title":"SuperLearner: Super Learner Prediction","author":"Polley","year":"2025"},{"key":"10.1016\/j.eprac.2026.04.004_bib18","doi-asserted-by":"crossref","DOI":"10.2202\/1544-6115.1309","article-title":"Super learner","volume":"6","author":"van der Laan","year":"2007","journal-title":"Stat Appl Genet Mol Biol"},{"issue":"4","key":"10.1016\/j.eprac.2026.04.004_bib19","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/0197-2456(96)00075-X","article-title":"A note on quantifying follow-up in studies of failure time","volume":"17","author":"Schemper","year":"1996","journal-title":"Control Clin Trials"},{"issue":"3","key":"10.1016\/j.eprac.2026.04.004_bib20","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1093\/biomet\/81.3.515","article-title":"Proportional hazards tests and diagnostics based on weighted residuals","volume":"81","author":"Grambsch","year":"1994","journal-title":"Biometrika"},{"issue":"3","key":"10.1016\/j.eprac.2026.04.004_bib21","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1001\/jama.2012.96867","article-title":"Prespecified falsification end points: can they validate true observational associations?","volume":"309","author":"Prasad","year":"2013","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.eprac.2026.04.004_bib22","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1097\/EDE.0b013e3181d61eeb","article-title":"Negative controls: a tool for detecting confounding and bias in observational studies","volume":"21","author":"Lipsitch","year":"2010","journal-title":"Epidemiol Camb Mass"},{"issue":"10","key":"10.1016\/j.eprac.2026.04.004_bib23","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1016\/j.numecd.2021.06.002","article-title":"Cardiovascular events and all-cause mortality in patients with type 2 diabetes treated with dipeptidyl peptidase-4 inhibitors: an extensive meta-analysis of randomized controlled trials","volume":"31","author":"Mannucci","year":"2021","journal-title":"Nutr Metab Cardiovasc Dis"},{"issue":"5","key":"10.1016\/j.eprac.2026.04.004_bib24","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0215248","article-title":"Risk of cardiovascular events associated with dipeptidyl peptidase-4 inhibitors in patients with diabetes with and without chronic kidney disease: a nationwide cohort study","volume":"14","author":"Huang","year":"2019","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.eprac.2026.04.004_bib25","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/s12933-019-0916-z","article-title":"Cardiovascular outcomes in trials of new antidiabetic drug classes: a network meta-analysis","volume":"18","author":"Fei","year":"2019","journal-title":"Cardiovasc Diabetol"},{"issue":"10","key":"10.1016\/j.eprac.2026.04.004_bib26","article-title":"Dipeptidyl peptidase-4 inhibitors, glucagon-like peptide 1 receptor agonists and sodium-glucose co-transporter-2 inhibitors for people with cardiovascular disease: a network meta-analysis","volume":"10","author":"Kanie","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.eprac.2026.04.004_bib27","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.diabres.2016.04.012","article-title":"Meta-analysis of dipeptidyl peptidase-4 inhibitors use and cardiovascular risk in patients with type 2 diabetes mellitus","volume":"116","author":"Kaneko","year":"2016","journal-title":"Diabetes Res Clin Pract"},{"issue":"3","key":"10.1016\/j.eprac.2026.04.004_bib28","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1111\/dom.16147","article-title":"Assessing the benefit-risk profile of newer glucose-lowering drugs: a systematic review and network meta-analysis of randomized outcome trials","volume":"27","author":"Tang","year":"2025","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.eprac.2026.04.004_bib29","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-95687-z","article-title":"Dipeptidyl peptidase-4 inhibitor cardiovascular safety in patients with type 2 diabetes, with cardiovascular and renal disease: a retrospective cohort study","volume":"11","author":"Baksh","year":"2021","journal-title":"Sci Rep"},{"issue":"10","key":"10.1016\/j.eprac.2026.04.004_bib30","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0240141","article-title":"Dipeptidyl peptidase-4 inhibitors and cardiovascular events in patients with type 2 diabetes, without cardiovascular or renal disease","volume":"15","author":"Baksh","year":"2020","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.eprac.2026.04.004_bib31","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0321032","article-title":"Cardiovascular and mortality outcomes of DPP-4 inhibitors vs. sulfonylureas as metformin add-on therapy in patients with type 2 diabetes: a systematic review and meta-analysis","volume":"20","author":"Hasan","year":"2025","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.eprac.2026.04.004_bib32","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/s44161-024-00453-9","article-title":"Effectiveness of glucose-lowering medications on cardiovascular outcomes in patients with type 2 diabetes at moderate cardiovascular risk","volume":"3","author":"McCoy","year":"2024","journal-title":"Nat Cardiovasc Res"},{"issue":"2","key":"10.1016\/j.eprac.2026.04.004_bib33","doi-asserted-by":"crossref","first-page":"206","DOI":"10.2215\/CJN.0000000587","article-title":"Kidney outcomes with glucagon-like Peptide-1 receptor agonists, sodium-glucose cotransporter 2 inhibitors, dipeptidyl Peptidase-4 inhibitors, and sulfonylureas in type 2 diabetes and moderate cardiovascular risk","volume":"20","author":"Neumiller","year":"2024","journal-title":"Clin J Am Soc Nephrol"},{"issue":"Supplement_1","key":"10.1016\/j.eprac.2026.04.004_bib34","first-page":"S181","article-title":"9. Pharmacologic approaches to glycemic treatment: standards of care in Diabetes\u20142025","volume":"48","year":"2024","journal-title":"Diabetes Care"},{"issue":"8","key":"10.1016\/j.eprac.2026.04.004_bib35","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.2337\/dc19-2419","article-title":"Efficacy of modern diabetes treatments DPP-4i, SGLT-2i, and GLP-1RA in white and Asian patients with diabetes: a systematic review and meta-analysis of randomized controlled trials","volume":"43","author":"Gan","year":"2020","journal-title":"Diabetes Care"}],"container-title":["Endocrine Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X26009389?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X26009389?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T00:27:49Z","timestamp":1793924869000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1530891X26009389"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":35,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S1530891X26009389"],"URL":"https:\/\/doi.org\/10.1016\/j.eprac.2026.04.004","relation":{},"ISSN":["1530-891X"],"issn-type":[{"value":"1530-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cardiovascular Effects of Alogliptin, Linagliptin, Saxagliptin, and Sitagliptin: A Target Trial Emulation of a Comparative Effectiveness Study","name":"articletitle","label":"Article Title"},{"value":"Endocrine Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eprac.2026.04.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 AACE. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}